T Illidge - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

T Illidge

Showing results (21-30 of 27) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 27 results.

British Journal of Cancer|October 19, 2013

A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicityA Gibb, A Greystoke, M Ranson, et al.

The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|January 30, 2013

Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphomaL Ferrer, E Malek, C Bodet-Milin, et al.

The British Journal of Dermatology|September 12, 2012

U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphomaJ J Scarisbrick, S Morris, R Azurdia, et al.

British Journal of Cancer|July 21, 2011

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisersK J Harrington, L J Billingham, T B Brunner, et al.

British Journal of Cancer|May 9, 2013

Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factorsR Cooke, M E Jones, D Cunningham, et al.

British Journal of Haematology|April 10, 2024

Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UKA Kuhnl, C Roddie, A A Kirkwood, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2021

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphomaS Horwitz, O A O'Connor, B Pro, et al.

Pageof 3